Out of 34 breast cancer patients assessed, those with BRCA2-001/Short expression in any tumor had significantly worse overall survival compared to patients whose tumors did not express this alternative isoform (p = 0.017, HR = 2.535, 95% CI 1.179–5.45) (Fig. 4g). This evidence concerns the gene BRCA2 and neoplasm.